Dr. Mark Robson on How DNA-Damaging Agents Function in Treating Breast Cancer
Mark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.
Mark Robson, MD, clinic director of the Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, talks about how DNA-damaging agents function in treating breast cancer.
Robson says the idea behind the treatment is specifically to exploit a defect in a particular repair pathway; when double-stranded damage is done to the DNA. He says another option to make DNA-damaging agents work is to create damage abnormalities that require double strand repair pathways.
Robson adds that these agents stand in contrast to PARP inhibitors, which are still being investigated by researchers to determine how they function.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
